全癌症药物反应预测使用整合性主要成分回归
bioRxiv : the preprint server for biology
|October 24, 2023
概括
精密瘤学使用细胞系数据来预测患者的药物反应. 我们的整合性主要成分回归 (iPCR) 模型弥合了细胞系和患者瘤之间的差距,改善了药物反应预测.
科学领域:
- 基因组学就是基因组学.
- 计算生物学 计算生物学
- 精确瘤学 精确瘤学
背景情况:
- 精确瘤学依赖于临床前癌症模型 (如细胞系) 的基因组和药理学数据.
- 细胞系虽然有用,但并不完全代表患者的瘤,在数据适用性方面造成了差距.
- 需要整合性方法来系统地评估患者瘤和细胞系之间的共同点.
研究的目的:
- 开发一种综合方法来评估细胞系和患者瘤之间的共享变异.
- 通过使用临床前药理学数据,提高对患者药物反应的预测.
- 确定关键的基因组驱动因素和与癌症药物反应相关的途径.
主要方法:
- 引入了整合性主要组件回归 (iPCR) 模型.
- 利用矩阵分解来发现基因组数据中的关节和模型特定变异.
- 员工提取了关节变异,以预测患者对药物的反应.
主要成果:
- 通过iPCR模型,成功地发现了细胞系和患者瘤之间的共享和模型特异性变异.
- 与现有方法相比,iPCR在预测患者药物反应方面表现良好.
- 确定了关键的驱动基因和与多种癌症治疗特异性反应相关的途径.
结论:
- 对于精确瘤学,iPCR模型有效地弥合了临床前模型和患者瘤之间的差距.
- iPCR增强了对患者药物反应的预测,并有助于识别治疗点.
- 该模型促进了共同表达网络的推断,并提供了对癌症药物反应驱动因素的可解释的见解.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K